Formulation, optimization and evaluation of pellets loaded glipizide co amorphous mixture using central composite design to enhance solubility

Year 2024, Volume: 28 Issue: 5, 1536 - 1549, 28.06.2025

Nahid Anjum Chishti İnayat Pathan , Mohamed Hassan Dehghan

Abstract

The objective of this study was to prepare a co-amorphous blend of BCS class II drug, glipizide (GPZ), using arginine (ARG) as co former. The co-amorphous GPZ-ARG mixtures (molar ratios 1:1, 1:2 and 2:1) were prepared by mechanical activation (ball milling) with different milling times. The obtained mixtures were characterized with respect to their thermal properties, possible molecular interactions, dissolution properties and physical stability and compared to the behaviour of pure crystalline form. Solid-state characterization of mixture revealed amorphization of GPZ after 90 min. of ball milling. GPZ-ARG co amorphous mixture (1:2) upon ball milling for 90 min. exhibited maximum solubility (3876.8 μg/ml) compared to pure drug (300.89 μg/ml). The resulting best co amorphous blend was incorporated into pellets which were prepared by extrusion spheronisation technique. The parameters related to process of pelletisation and product related parameters were optimized by using 4-factor, 5-level Central Composite Design. The pellets containing co amorphous blend, prepared by using optimal parameter settings, showed 95.67% Drug Release in 120 min. (F23). The co-amorphous mixture and the optimized formulation were found to be stable when subjected to stability study as per ICH guideline. It was concluded that co amorphous is a promising approach to overcome the solubility constraint of Glipizide which would be helpful in better management of the disease.

Keywords

Glipizide , Co-amorphous , Central Composite Design , ball milling , pellets

References

• [1] Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1. https://doi.org/10.1021/js9601896
• [2] Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: Molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst. 2004;21(3):133–193. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
• [3] Zhang GGZ, Law D, Schmitt EA, Qiu Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev. 2004;56(3):371–390. https://doi.org/10.1016/j.addr.2003.10.009
• [4] Jensen KT, Löbmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, Proline. Pharmaceutics. 2014;6(3):416–435. https://doi.org/10.3390/pharmaceutics6030416
• [5] Löbmann K, Laitinen R, Grohganz H, Gordon KC, Strachan C, Rades T. Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8(5):1919–1928. https://doi.org/10.1021/mp2002973
• [6] Löbmann K, Strachan C, Grohganz H, Rades T, Korhonen O, Laitinen R. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012;81(1):159–169. https://doi.org/10.1016/j.ejpb.2012.02.004
• [7] Qian S, Heng W, Wei Y, Zhang J, Gao Y. Coamorphous lurasidone hydrochloride-saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with ph-independent solubility behavior. Cryst Growth Des. 2015;15(6):2920–2928. https://doi.org/10.1021/acs.cgd.5b00349
• [8] Hatwar P, Pathan IB, Chishti NAH, Ambekar W. Pellets containing quercetin amino acid co-amorphous mixture for the treatment of pain: Formulation, optimization, in-vitro and in-vivo study. J Drug Deliv Sci Technol. 2021;62:102350. https://doi.org/10.1016/j.jddst.2021.102350
• [9] Singh G, Pai RS, Kusum Devi V. Optimization of pellets containing solid dispersion prepared by extrusion/spheronization using central composite design and desirability function. J Young Pharm. 2012;4(3):146–156. https://doi.org/10.4103/0975-1483.100020
• [10] Schilling SU, Shah NH, Waseem Malick A, McGinity JW. Properties of melt extruded enteric matrix pellets. Eur J Pharm Biopharm. 2010;74(2):352–361. https://doi.org/10.1016/j.ejpb.2009.09.008
• [11] Gotti R, Furlanetto S, Andrisano V, Cavrini V, Pinzauti S. Design of experiments for enantioresolution of salbutamol using dermatan sulfate in capillary electrophoresis. J Pharm Belg. 1998;53(3):190. https://doi.org/10.1016/s00219673(99)01303-5
• [12] Rahim H, Sadiq A, Ullah R, Bari A, Amin F, Farooq U, Ullah Jan N, Mahmood HM. Formulation of aceclofenac tablets using nanosuspension as granulating agent: An attempt to enhance dissolution rate and oral bioavailability. Int J Nanomedicine. 2020 Nov 17;15:8999-9009. https://doi.org/10.2147/IJN.S270746
• [13] Dash RN, Mohammed H, Humaira T, Ramesh D. Design, optimization and evaluation of glipizide solid self nanoemulsifying drug delivery for enhanced solubility and dissolution. Saudi Pharm J. 2015;23(5):528–540. https://doi.org/10.1016/j.jsps.2015.01.024
• [14] Karagianni A, Kachrimanis K, Nikolakakis I. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: Composition, preparation, characterization and formulations for oral delivery. Pharmaceutics. 2018;10(3):98. https://doi.org/10.3390/pharmaceutics10030098
• [15] Korhonen O, Pajula K, Laitinen R. Rational excipient selection for co-amorphous formulations. Expert Opin Drug Deliv. 2017;14(4):551-569. https://doi.org/10.1080/17425247.2016.1198770
• [16] Heinz A, Strachan CJ, Gordon KC, Rades T. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol. 2009;61(8):971–988. https://doi.org/10.1211/jpp/61.08.0001
• [17] Zhu S, Gao H, Babu S, Garad S. Co-amorphous formation of high-dose zwitterionic compounds with amino acids to improve solubility and enable parenteral delivery. Mol Pharm. 2018;15(1):97-107. https://doi.org/10.1021/acs.molpharmaceut.7b00738
• [18] Laitinen R, Löbmann K, Grohganz H, Priemel P, Strachan CJ, Rades T. Supersaturating drug delivery systems: The potential of co-amorphous drug formulations. Int J Pharm. 2017;532(1):1–12. https://doi.org/10.1016/j.ijpharm.2017.08.123
• [19] Hausner HH. Friction Conditions in a Mass of Metal Powder. Int J Powder Metall. 1967;3:7–13.
• [20] Hirano A, Kameda T, Arakawa T, Shiraki K. Arginine-assisted solubilization system for drug substances: Solubility experiment and simulation. J Phys Chem B. 2010;114(42):13455–13462. https://doi.org/10.1080/17425247.2016.1198770
• [21] Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-1075. https://doi.org/10.1016/j.drudis.2007.09.005
• [22] Kilor VA, Sapkal NP, Awari JG, Shewale BD. Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using κ-carrageenan as a pelletizing agent. AAPS PharmSciTech. 2010;11(1):336–343. https://doi.org/10.1208/s12249-010-9389-9
• [23] Ibrahim MA, El-badry M. Formulation of immediate release pellets containing famotidine solid dispersions. Saudi Pharm J. 2014;22(2):149–156. http://dx.doi.org/10.1016/j.jsps.2013.01.011
• [24] Law MFL, Deasy PB. Use of canonical and other analyses for the optimization of an extrusion-spheronization process for indomethacin. Int J Pharm. 1997;146(1):1–9. https://doi.org/10.1016/S0378-5173(96)04741-2
• [25] Gowda DV, Rajesh N, Moin A, Shivakumar HG, Siddaramaiah. Controlled release behaviour of nifedipine from the pellets of gelucire/microcrystalline cellulose blends. Int J PharmTech Res. 2010;2(2):1215–1226. https://doi.org/10.1208/pt0803051
• [26] Singh R, Poddar SS, Chivate A. Sintering of wax for controlling release from pellets. AAPS PharmSciTech. 2007;8(3):E175-E183. https://doi.org/10.1208/pt0803051
• [27] Mandal U, K. Gowda V, Ghosh A, Senthamıl SP, Sam Solomon W, Pal T. Development of dissolution medium for glipizide. Asian J Chem. 2010;20(4):2651–2656.
• [28] CPMP/ICH. ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products. Eur Med Agency. 1998;(January):1–14.
• [29] Pathan IB, Munde SJ, Shelke S, Ambekar W, Mallikarjuna Setty C. Curcumin loaded fish scale collagen-HPMC nanogel for wound healing application: Ex-vivo and In-vivo evaluation. Int J Polym Mater Polym Biomater. 2019;68(4):165–174. https://doi.org/10.1080/00914037.2018.1429437